Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date |
Reported DateTime |
Company | Symbol | Insider Relationship |
Shares Traded |
Average Price |
Total Amount |
Shares Owned |
Filing |
| 2020-12-28 Sale |
2021-02-16 4:11 pm |
Aprea Therapeutics Inc. | APRE | Redmile Group LLC Green Jeremy 10% Owner |
500,000 | $5.5826 | $2,791,290 | 1,768,718 (Indirect) |
View |
| 2020-10-05 Sale |
2020-10-07 9:30 pm |
Aprea Therapeutics Inc. | APRE | 5AM Ventures IV L.P. 5AM Co-Investors IV L.P. 5AM Partners IV LLC 5AM Opportunities I L.P. 5AM Opportunities I (GP) LLC DIEKMAN JOHN D Schwab Andrew J. PARMAR KUSH ROCKLAGE SCOTT M Former 10% holder |
175,000 | $25.3 | $4,427,500 | 2,037,654 (Indirect) |
View |
| 2020-07-07 Sale |
2020-07-07 5:41 pm |
Aprea Therapeutics Inc. | APRE | KDev Investments AB Karolinska Development AB KCIF Co-Investment Fund KB 10% Owner |
241,703 | $34.55 | $8,350,839 | 1,992,586 (Indirect) |
View |
| 2020-06-16 Sale |
2020-06-18 7:23 pm |
Aprea Therapeutics Inc. | APRE | ROCKLAGE SCOTT M Director 10% Owner |
120,164 | $33.3 | $4,001,461 | 75,965 (Indirect) |
View |
| 2020-06-16 Sale |
2020-06-18 7:22 pm |
Aprea Therapeutics Inc. | APRE | 5AM Ventures IV L.P. 5AM Co-Investors IV L.P. 5AM Partners IV LLC DIEKMAN JOHN D Schwab Andrew J. 5AM Opportunities I L.P. 5AM Opportunities I (GP) LLC PARMAR KUSH 10% Owner |
140,000 | $33.3 | $4,662,000 | 313,497 (Indirect) |
View |
| 2020-06-11 Sale |
2020-06-15 9:13 pm |
Aprea Therapeutics Inc. | APRE | ROCKLAGE SCOTT M Director 10% Owner |
245,000 | $28.75 | $7,044,412 | 80,772 (Indirect) |
View |
| 2020-06-11 Sale |
2020-06-15 9:12 pm |
Aprea Therapeutics Inc. | APRE | 5AM Ventures IV L.P. 5AM Co-Investors IV L.P. 5AM Partners IV LLC DIEKMAN JOHN D Schwab Andrew J. 5AM Opportunities I L.P. 5AM Opportunities I (GP) LLC PARMAR KUSH 10% Owner |
245,000 | $28.75 | $7,044,412 | 414,105 (Indirect) |
View |
| 2020-05-19 Sale |
2020-05-21 9:32 pm |
Aprea Therapeutics Inc. | APRE | ROCKLAGE SCOTT M Director |
255,000 | $35.15 | $8,963,250 | 90,572 (Indirect) |
View |
| 2020-05-19 Sale |
2020-05-21 9:31 pm |
Aprea Therapeutics Inc. | APRE | 5AM Ventures IV L.P. 5AM Co-Investors IV L.P. 5AM Partners IV LLC DIEKMAN JOHN D Schwab Andrew J. 5AM Opportunities I L.P. 5AM Opportunities I (GP) LLC PARMAR KUSH 10% Owner |
255,000 | $35.15 | $8,963,250 | 423,905 (Indirect) |
View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date |
Reported DateTime |
Exercisable Expiration |
Company | Symnbol | Insider Relationship |
Shares Traded |
Conversion Price |
Shares Owned |
Filing |
| 2021-08-25 Tax Withholding |
2021-08-27 5:00 pm |
N/A N/A |
Aprea Therapeutics Inc. | APRE | Attar Eyal C. SVP, Chief Medical Officer |
9,032 | $3.98 | 99,299 (Direct) |
View |
| 2021-06-30 Option Award |
2021-07-01 7:09 pm |
N/A 2031-06-30 |
Aprea Therapeutics Inc. | APRE | HENNEMAN JOHN B III Director |
27,360 | $0 | 32,360 (Direct) |
View |
| 2021-06-30 Option Award |
2021-07-01 7:07 pm |
N/A 2031-06-30 |
Aprea Therapeutics Inc. | APRE | Kelly Michael Aaron Director |
27,360 | $0 | 27,360 (Direct) |
View |
| 2021-06-30 Option Award |
2021-07-01 7:02 pm |
N/A 2031-06-30 |
Aprea Therapeutics Inc. | APRE | Peters Richard Director |
27,360 | $0 | 27,360 (Direct) |
View |
| 2021-06-30 Option Award |
2021-07-01 7:00 pm |
N/A 2031-06-30 |
Aprea Therapeutics Inc. | APRE | Seizinger Bernd R. Director |
27,360 | $0 | 291,330 (Direct) |
View |
| 2021-06-30 Option Award |
2021-07-01 6:58 pm |
N/A 2031-06-30 |
Aprea Therapeutics Inc. | APRE | Namouni Fouad Director |
27,360 | $0 | 27,360 (Direct) |
View |
| 2021-03-10 Option Award |
2021-03-11 5:30 pm |
N/A N/A |
Aprea Therapeutics Inc. | APRE | Korbel Gregory Alan Chief Business Officer |
15,000 | $0 | 25,500 (Direct) |
View |
| 2021-02-25 Option Award |
2021-03-01 7:12 pm |
N/A 2031-02-25 |
Aprea Therapeutics Inc. | APRE | Attar Eyal C. SVP, Chief Medical Officer |
251,000 | $0 | 251,400 (Direct) |
View |
| 2021-02-25 Option Award |
2021-03-01 7:10 pm |
N/A 2031-02-25 |
Aprea Therapeutics Inc. | APRE | Wessels Gregory S. SVP, Chief Commercial Officer |
82,000 | $0 | 82,000 (Direct) |
View |
| 2021-02-25 Option Award |
2021-03-01 7:08 pm |
N/A 2031-02-25 |
Aprea Therapeutics Inc. | APRE | Abrahmsen Lars B. SVP, Chief Scientific Officer |
101,000 | $0 | 101,000 (Direct) |
View |
| 2021-02-25 Option Award |
2021-03-01 7:05 pm |
N/A 2031-02-25 |
Aprea Therapeutics Inc. | APRE | SCHADE CHRISTIAN S Chairman & CEO |
494,500 | $0 | 516,660 (Direct) |
View |
| 2021-02-25 Option Award |
2021-03-01 7:03 pm |
N/A 2031-02-25 |
Aprea Therapeutics Inc. | APRE | Coiante Scott M SVP, Chief Financial Officer |
239,500 | $0 | 242,000 (Direct) |
View |
| 2021-02-25 Option Award |
2021-03-01 7:01 pm |
N/A 2031-02-25 |
Aprea Therapeutics Inc. | APRE | Korbel Gregory Alan VP of Business Dev't |
51,100 | $0 | 51,600 (Direct) |
View |
| 2020-09-28 Option Award |
2020-09-29 5:01 pm |
N/A 2030-09-28 |
Aprea Therapeutics Inc. | APRE | Kelly Michael Aaron Director |
12,000 | $0 | 12,000 (Direct) |
View |
| 2020-09-16 Option Award |
2020-09-18 5:05 pm |
N/A 2030-09-16 |
Aprea Therapeutics Inc. | APRE | Wessels Gregory S. SVP, Chief Commercial Officer |
14,700 | $0 | 14,700 (Direct) |
View |
Ownership |
2020-09-18 5:04 pm |
N/A 2030-02-10 |
Aprea Therapeutics Inc. | APRE | Wessels Gregory S. SVP, Chief Commercial Officer |
0 | $0 | 30,000 (Direct) |
View |
| 2020-06-30 Option Award |
2020-07-01 6:08 pm |
N/A 2030-06-30 |
Aprea Therapeutics Inc. | APRE | HENNEMAN JOHN B III Director |
5,600 | $0 | 5,600 (Direct) |
View |
| 2020-06-30 Option Award |
2020-07-01 6:06 pm |
N/A 2030-06-30 |
Aprea Therapeutics Inc. | APRE | Seizinger Bernd R. Director |
5,600 | $0 | 5,600 (Direct) |
View |
| 2020-06-30 Option Award |
2020-07-01 6:03 pm |
N/A 2030-06-30 |
Aprea Therapeutics Inc. | APRE | Hepple Jonathan Director |
5,600 | $0 | 5,600 (Direct) |
View |
| 2020-06-30 Option Award |
2020-07-01 6:01 pm |
N/A 2030-06-30 |
Aprea Therapeutics Inc. | APRE | Christenson Johan Director |
5,600 | $0 | 5,600 (Direct) |
View |
| 2020-06-30 Option Award |
2020-07-01 4:55 pm |
N/A 2030-06-30 |
Aprea Therapeutics Inc. | APRE | ROCKLAGE SCOTT M Director |
5,600 | $0 | 5,600 (Direct) |
View |
| 2020-06-26 Option Award |
2020-06-29 6:05 pm |
N/A 2030-06-26 |
Aprea Therapeutics Inc. | APRE | Namouni Fouad Director |
7,000 | $0 | 7,000 (Direct) |
View |
| 2020-06-26 Option Award |
2020-06-29 6:04 pm |
N/A 2030-06-26 |
Aprea Therapeutics Inc. | APRE | Peters Richard Director |
7,000 | $0 | 7,000 (Direct) |
View |
| 2020-05-18 Other |
2020-05-20 9:58 pm |
N/A N/A |
Aprea Therapeutics Inc. | APRE | Versant Vantage I L.P. Versant Vantage I GP L.P. Versant Vantage I GP-GP LLC 10% Owner |
120,148 | $0 | 340,301 (Direct) |
View |